NOTIFICATION TO STOCK EXCHANGE
COMPANY STATEMENT
Bengaluru, Karnataka, India, September 25, 2026
Biocon Limited (BSE code: 532523, NSE: BIOCON) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA), UK for its new drug product fill finish unit for Semglee® (insulin glargine) at its insulin manufacturing facility in Malaysia.
In July, Biocon had secured regulatory approval from the European Medicines Agency (EMA) for this new drug product fill-finish line.